OneSource Specialty Pharma Q1 FY27 Earnings Call Transcript Released
OneSource Specialty Pharma reported Q1 FY27 revenues of ₹4,490 million, up 37% YoY, and EBITDA of ₹1,233 million, up 39% YoY. The growth was driven by semaglutide commercial launch and new contracts. The company is expanding capacity with a second cartridge line coming online, doubling sterile days. They reiterated their FY28 outlook of $400 million organic revenue and 40% EBITDA margins.
The announcement details significant revenue growth, successful capacity expansions, new customer acquisitions, and reiteration of strong future financial targets. These are material factors that are likely to influence investor perception and the company's stock performance.
The company reported strong year-on-year revenue and EBITDA growth, highlighted successful product launches and commercialization efforts, and reiterated positive future financial outlooks. Capacity expansions and new customer wins further support a positive sentiment.
OneSource Specialty Pharma Limited has released the transcript of its earnings call for the quarter ended June 30, 2026. The call, which took place on July 25, 2026, followed a Board of Directors meeting on July 24, 2026.
During the call, Mr. Neeraj Sharma, CEO and MD, reported that the quarter was strong, with revenues reaching ₹4,490 million, a 37% year-on-year increase. This growth was attributed to the commercial launch of semaglutide, new MSA contracts, and new customer wins. EBITDA stood at ₹1,233 million, up 39% year-on-year and 34% sequentially.
The company highlighted the significant step-up in semaglutide commercialization in Canada, the largest off-patent market. Two partners have already launched, and in India, over 40% of generic pens sold as of June 26 are manufactured at their site. Despite a temporary disruption in supplies from Dr. Reddy's, OneSource's available capacities remained full due to a diverse customer base.
The first phase of a US$100 million capex is nearing completion, with the second cartridge line set for commercialization this quarter, doubling sterile days available for production. This expansion will support supplies to Dr. Reddy's and other countries, and enable the onboarding of new customers. Within FY27, another line will be installed, positioning OneSource as a global CDMO with complete end-to-end capabilities.
The company also emphasized the strength in complex peptide development and drug device capabilities, with two customers achieving first-to-file status in the US for tirzepatide. In the biologics segment, a partnership with Formycon was highlighted, aiming to expand access to high-quality, affordable biologics. The RFP funnel for biologics is reported to be 4x larger than a year ago.
OneSource Specialty Pharma saw nine new launches and added six new logos in the quarter. The company maintained an exemplary compliance record, with 12 successful inspections, including two surprise FDA audits. The company reiterated its FY28 outlook of $400 million in organic revenue and 40% EBITDA margins.
During the Q&A session, discussions included the performance of the soft gelatin business, margin improvements in injectables, the impact of customer-specific disruptions, order book visibility, and capacity utilization across various segments. The company also provided insights into its long-term strategy beyond FY28, focusing on the growth potential of its biologics and drug device combination businesses, and potential capacity expansions.
What to do with a filing like this
Onesource Specialty Pharma Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Onesource Specialty Pharma Limited. Read the original for the full detail.